SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

The SYNERGY Stent is designed so its attributes synergistically work together to promote optimal healing within the vessel.1

Explore

Product Details

Heal with confidence Heal with confidence

Because you never know when life will become complex

Drug-eluting stent technology has shown encouraging efficacy compared to bare metal stents, significantly reducing restenosis and revascularization procedures. Still, there remains a concern for being able to treat ever-increasing complex lesions, ensuring proper healing, and managing dual antiplatelet therapy (DAPT).

What if there was a technology that offered the benefits of being able to improve the ability to acutely treat complex lesions, improve the healing properties, and potentially free selected patients from long-term DAPT?** 

Introducing the SYNERGY Stent

Designed to help patients, including those with complex cases, heal from day one and beyond.

Ordering Information

  STENT LENGTH  
ø 
(mm)
8 12 16 20 24 28 32 38 Over
Expansion
Capability
2.25 H7493926208220 H7493926212220 H7493926216220 H7493926220220 H7493926224220 H7493926228220 H7493926232220 H7493926238220 3.50
2.50 H7493926208250 H7493926212250 H7493926216250 H7493926220250 H7493926224250 H7493926228250 H7493926232250 H7493926238250 3.50
2.75 H7493926208270 H7493926212270 H7493926216270 H7493926220270 H7493926224270 H7493926228270 H7493926232270 H7493926238270 3.50
3.00 H7493926208300 H7493926212300 H7493926216300 H7493926220300 H7493926224300 H7493926228300 H7493926232300 H7493926238300 4.25
3.50 H7493926208350 H7493926212350 H7493926216350 H7493926220350 H7493926224350 H7493926228350 H7493926232350 H7493926238350 4.25
4.00 H7493926208400 H7493926212400 H7493926216400 H7493926220400 H7493926224400 H7493926228400 H7493926232400 H7493926238400 5.75

Clinical Information

SYNERGY Stent Clinical Program and Research

Addressing the full spectrum of cardiovascular disease complexity

The SYNERGY Stent design goals are to address needs surrounding complex PCI. As a result, Boston Scientific established a robust clinical trial program and is supporting investigator-sponsored research5 (ISR) that will study the SYNERGY Stent in many different patient populations that interventional cardiologists see in their everyday practice.

Complex Lesions

The SYNERGY Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease, including patients with acute myocardial infarction and patients with concomitant diabetes mellitus due to discrete de novo native coronary artery lesions. The SYNERGY Stent System is also indicated for treatment of patients presenting with:

Complex Patients - SYNERGY Indications Complex Patients - SYNERGY Indications

Added recommendations include: For treatment of occluded vessels, contrast visualization of the distal vessel to confirm position of guidewire within the lumen is recommended. For in stent restenosis, where details of the original stent are known, the expanded inner diameter of the new stent should not exceed the dilation limits of the original stent. Where details of the original stent are not known, the expanded inner diameter of the new stent should not exceed the reference vessel diameter. When treating Bifurcations, care must be exercised to access the secondary vessel via the repeating geometry in the body of the stent within the primary vessel.

SYNERGY DAPT Labelling Update - Now CE Marked SYNERGY DAPT Labelling Update - Now CE Marked

^ The updated Directions for Use will also include an update on the current “Pre-and Post-Procedure Antiplatelet Regimen”:
In selected higher risk patients where the physician determines that the risks outweigh the benefits of continued DAPT, it may be reasonable to interrupt or discontinue therapy after 1 month based on low stent thrombosis rates and no observed increased risk for stent thrombosis as shown in the current literature.  Patients who require premature discontinuation of antiplatelet therapy should be monitored closely and have their antiplatelet therapy restarted as soon as possible per the discretion of their treating physicians.

Top